Payment & Shipping Terms:
|Type:||Pharmaceutical Powder||Appearance:||White Powder|
|Usage:||Treating Hair Loss||Alias:||Ru58841|
anti estrogen steroids,
hair growing powder
|Product Name:||R 1|
|Synonyms:||4-(4,4-Dimethyl-2,5-dioxo-3-(4-hydroxybutyl)1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; RU58841; 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile|
|Boiling Point(C):||493.6C at 760 mmHg|
Product Name: RU-58841
BP: 493.6°C at 760 mmHg
Grade: Pharmaceutical Grade
Appearance: White Powder
RU58841 is a specific androgen receptor antagonist or a so called anti-androgen. This non steroidal topical androgen antagonist was investigated for therapeutic value in androgenetic alopecia and acne. In studies and clinical trials RU58841 has shown to:
Anti-hair loss products
Description: Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling
Cortexolone 17 alpha-propionate (CB-03-01) is a new topical and peripherally selective androgen receptor antagonist.
RU58841 works by binding to the androgen receptor in the hair follicle. Therefore androgens don't have the chance to bind and start the chain reaction of androgenetic alopecia and begin the so called miniaturization process. It has been demonstrated to interrupt this hair loss message locally so that normal hair growth could continue.
OC000459 for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of OC000459 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to OC000459 and the treatment of acne and prostate cancer, which are conditions also driven by, however, the most recent study published in relation to OC000459 was back in 2008.
Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells) antagonist. CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. Thus, antagonism of CRTH2 receptors is considered to be a promising therapeutic target for various allergic diseases and asthma.
Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.
Contact Person: bruce